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Abstract
Background: There have been many studies supporting fluconazole prophylaxis in preterm infants for prevention
of invasive fungal infections (IFIs). However, the routine use of fluconazole prophylaxis in neonatal intensive care
units (NICUs) raises concerns with respect to resistance development, including the selection of resistant Candida
species. We aimed to evaluate the efficacy and safety of fluconazole prophylaxis in extremely low birth weight
(ELBW) infants.
Methods: An interventional pre-post cohort study at two tertiary NICUs was conducted. Data from two 5-year
periods with and without fluconazole prophylaxis (Mar 2008–Feb 2013 and Mar 2003–Feb 2008) was compared.
Prophylactic fluconazole was administered starting on the 3rd day at a dose of 3 mg/kg twice a week for 4 weeks
during the prophylaxis period.
Results: The fluconazole prophylaxis group consisted of 264 infants, and the non-prophylaxis group consisted of
159 infants. IFI occurred in a total of 19 neonates (4.7 %) during the 10-year study period. Fluconazole prophylaxis
lower the fungal colonization rate significantly (59.1 % vs. 33.9 %, P <0.001). However, the incidence of IFIs in ELBW
infants was not reduced after fluconazole prophylaxis (4.4 % vs. 5.5 %, P = 0.80). Rather, although the increase did
not reach statistical significance, fluconazole prophylaxis tended to increase the incidence of invasive infections
involving fluconazole-resistant C. parapsilosis (0 % vs. 41.7 %, P = 0.11).
Conclusions: Fluconazole prophylaxis was not efficacious in decreasing IFIs in ELBW infants. There is a need for
targeting prophylaxis to greatest risk population and prospective studies to measure the long-term effect of
fluconazole prophylaxis on the emergence of organisms with antifungal resistance.
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Background
Preterm infants managed in a neonatal intensive care
unit (NICU) are at significant risk of invasive fungal in-
fection (IFI) because of invasive vascular procedures,
broad-spectrum antibiotic treatments, prolonged paren-
teral nutrition, and most importantly, their immature
immune systems. For the highest-risk group, extremely
low birth weight (ELBW, <1,000 g at birth) infants, IFI is
attributable to increase mortality and neurodevelopmen-
tal impairment, despite antifungal therapy [1–3]. Several
well-designed randomized trials and meta-analyses have
shown that antifungal prophylaxis with fluconazole re-
duces the incidence of IFIs [4–7]. Of note, studies exam-
ining fluconazole prophylaxis have been conducted in
NICUs with relatively high incidences of IFIs (13–20 %)
[4–6]. However, several large cohort studies have re-
ported IFI incidences as low as < 5 % for ELBW infants
[3, 8–10]. and a recent study has demonstrated a sub-
stantial decrease in IFI incidence in the last 14 years due
to improved perinatal and intensive care for preterm in-
fants [11].
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Meanwhile, with respect to fluconazole prophylaxis,
there has been concern regarding the emergence of re-
sistance to azoles, including the selection for and re-
placement of resistant Candida spp. in preterm infants
[12, 13]. Other concerns are short-term drug toxicities
and long-term neurodevelopmental consequences of flu-
conazole when it is used in a “developing immature or-
ganism” [14, 15].
We have implemented fluconazole prophylaxis as part
of our routine management of ELBW infants since
March 2008. We reviewed the clinical data and details of
IFIs of infants receiving fluconazole prophylaxis after
adopting this practice and compared them to a historical
control group of the pre-prophylaxis period. We aimed
to evaluate whether fluconazole prophylaxis did decrease
the incidence of IFIs in ELBW infants. Moreover, we in-
vestigated IFIs involving fluconazole-resistant strains,
potential adverse effects of fluconazole, and long-term
morbidities as aspects related to drug safety.
Methods
Study population and study setting
This interventional pre-post cohort study with a histor-
ical control was conducted at two tertiary NICUs, at
which the same intervention protocol was applied. The
study cohort included all ELBW infants who were born
in and admitted to the NICUs of Seoul National Univer-
sity Children’s Hospital and Seoul National University
Bundang Hospital between March 2003 and February
2013. We excluded infants prenatally exposed to anti-
fungal agents, those receiving therapeutic antifungal
agents within 3 days after birth, and those who died be-
fore 3 days of life. The study was approved by the Insti-
tutional Review Board of Seoul National University
Hospital and informed consent was waived.
As a routine practice protocol, all ELBW infants
underwent weekly surveillance culture studies. All clin-
ical and microbiological records for the infants, includ-
ing surveillance fungal isolate data during the NICU
stay, were collected. All of the admitted ELBW infants
received fluconazole prophylaxis starting in March 2008.
A comparison was made between the two different pe-
riods (i.e., the pre-prophylaxis period, March 2003
through February 2008; and the prophylaxis period,
March 2008 through February 2013).
The standard regimen for fluconazole prophylaxis was
3 mg/kg (Diflucan™, Pfizer Inc., Seoul, Korea or Oneflu™,
JW Pharmaceutical, Seoul, Korea) administered once a
day intravenously if a catheter was present, or through
an orogastric tube, starting on the 3rd postnatal day [6],
twice a week for 4 weeks. For cases of a presumed or
proven IFI, fluconazole was suspended, and systemic an-
tifungal therapy with non-liposomal or liposomal
amphotericin B was administered empirically in both
periods. For proven IFI, in uncomplicated cases, treat-
ment was continued for 14 days after the last positive
blood culture.
During the 10-year study period, there were no
changes in infection control practices within both two
NICUs. All NICU patients were screened regularly for
occurrence of invasive infections, so that infants with
antibiotics-resistant organism colonization could be
placed in an isolation room with contact isolation proce-
dures. Central venous catheters were placed and main-
tained sterilely according to the strict guidelines, and
removals of their central venous catheters were dis-
cussed daily. All of the parenteral nutrition was prepared
in pharmacy with aseptic technique and their qualities
had been checked regularly on the base of the national
administration regulations for level III centers.
Identification of fungal colonization and infection
Surface cultures were routinely obtained from the fol-
lowing five body sites: the axilla, external ear canal,
nasopharynx, throat (or tracheal aspirate if intubated)
and anus. All of the procedures were performed with
sterile transport swabs (COPAN Italia SpA, Brescia,
Italy) or disposable respiratory specimen traps (HYUP
SUNG Medical, Yangju, Kyunggi, Korea) for tracheal as-
pirates. The specimens were transported to microbio-
logical laboratories within 30 min. Baseline surface
cultures were obtained within 48 hours of birth from
ELBW infants. Follow-up cultures were taken weekly for
one month, and additional cultures were obtained
weekly for infants with a central venous catheter. Fungal
colonization was defined by a positive surveillance cul-
ture at any site, at any time during hospitalization. A
positive culture from urine collected through urine bags
(if <105 CFUs/mL) was also considered indicative of fun-
gal colonization.
For every episode of suspected sepsis, two or more
blood samples from different sites were obtained, in
addition to urine samples through either urine bags or
an in/out catheter. The blood specimens were processed
by clinical microbiology laboratories using a BacT/Alert
3D (Organon Teknika, Durham, NC, USA) system. For
fungal isolation, Sabouraud-dextrose agar (SDA) and
SDA-chloramphenicol plates were used. After isolation
of grown fungi, yeasts were processed using a VITEK 2
system for both the identification and determination of
antifungal susceptibility. If the result of susceptibility test
using the VITEK 2 system was “resistant” or “intermedi-
ate”, an E-test was performed using Clinical Laboratory
Standards Institute breakpoints. The interpretative break-
points of fluconazole resistance were defined as ≥ 64 μg/
mL, as recommended by National Committee for Clinical
Laboratory Standards [16]. Molds were identified through
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morphological analysis after lacto-phenol cotton blue
staining.
Study outcomes
The primary outcome for the efficacy of fluconazole
prophylaxis was the incidence of IFIs, which was defined
by at least one positive culture from blood, urine
(>105 CFUs/mL in urine bags or 104 CFUs/mL in an in/
out catheter), ascites, pleural fluid or cerebrospinal fluid,
accompanied by at least two clinical signs of systemic in-
flammatory responses (apnea, bradycardia, temperature
≥38.0 or ≤36.0 °C, blood sugar level ≥160 or ≤50 mg/
dL). We also evaluated death from IFIs, the fungal
colonization rate and respective species, the progression
of fungal colonization to IFI, the length of NICU stay
and mortality.
The primary safety outcome was the rates of IFIs in-
volving fluconazole-resistant strains. We also measured
the colonization rate of fluconazole-resistant fungi and
the incidence of acute adverse events, including liver
dysfunction (AST or ALT >250 IU/L) [17], renal dys-
function (creatinine >1.5 mg/dL), and cholestasis (direct
bilirubin >2 mg/dL), which were assessed by weekly
serum samples during the first 6 weeks. The incidence
of skin rash, a known adverse reaction of fluconazole,
was also determined. We collected data on rickets of
prematurity based on a wrist X-ray at 4 weeks of age.
Also included in analysis were late developmental mor-
bidities (cerebral palsy, blindness, deafness and catch-up
growth failure), which were assessed at 18 to 22 months
of corrected age. Cerebral palsy was defined as a non-
progressive disorder characterized by abnormal tone in
at least one extremity and abnormal control of move-
ment and posture. Blindness was defined as no func-
tional vision in either eye. Deafness was defined as an
inability to understand commands despite amplification,
hearing aids, or cochlear implants in both ears. Failure
of catch-up growth was defined as a weight of below the
10th percentile of the standardized growth curve.
Statistical analysis
For 264 infants in the groups receiving fluconazole and
159 infant in the group not receiving fluconazole, we es-
timated that we would have at least 90 % power to de-
tect differences in IFI rates based on previous reports
[18, 19]. Statistical analysis was performed with SAS ver-
sion 9.1.3 (SAS Institute, Cary, NC, USA) and SPSS ver-
sion 21.0 (SPSS, Chicago, IL, USA). Categorical variables
were analyzed using χ2 and Fisher’s exact test, as appro-
priate. Continuous variables were analyzed using the in-
dependent t-test and Wilcoxon rank sum test, as
appropriate. Multivariate logistic regression was used to
assess the significance of the variables. P <0.05 was con-
sidered statistically significant.
Results
Of 470 ELBW infants during the study period, 47 were ex-
cluded from analysis. The fluconazole group consisted of
264 infants born during the period of prophylaxis use, and
the pre-prophylaxis control group consisted of 159 infants
who did not receive fluconazole prophylaxis (Fig. 1).
The demographic and clinical characteristics of both
groups are shown in Table 1. There were no significant
differences in the baseline characteristics between the
two groups, except for antenatal steroid use. More in-
fants were exposed to antenatal steroids in the flucona-
zole group (87 % vs. 72 %, P <0.001). Infants in the
fluconazole group had fewer risk factors for fungal infec-
tion in their clinical courses, as defined by many previ-
ous reports; less frequently used H2 blockers (39 % vs.
69 %, P <0.001), 3rd generation cephalosporin (5 % vs.
26 %, P <0.001) and vancomycin (49 % vs. 60 %, P =
0.03) compared with those in the control group. The
days to reach full enteral feeding (mean ± SD, 26 ± 16 vs.
31 ± 17 days, P = 0.001) and antibiotic duration (mean ±
SD, 19 ± 20 vs. 28 ± 26 days, P <0.001) were also shorter
in the fluconazole group compared with the control
group, and the number of infants who received oxygen
therapy for over 48 hours after birth was significantly
lower in the fluconazole group (87 % vs. 94 %, P = 0.02).
In a total of 19 ELBW neonates (4.7 %), 21 episodes of
IFIs occurred during the 10-year study period. The dis-
tribution of fungal spp. causing infection, their sensitiv-
ities to fluconazole, and details of the IFIs are reported
in Table 2. The most frequently identified species was C.
parapsilosis (3 cases in the control group [42.9 %] and 9
in the fluconazole group [75.0 %], P = 0.33). Fluconazole-
resistant C. parapsilosis was found in 5 cases (41.7 %) in
the fluconazole group, and in none in the control group
(P = 0.11). Although 28.6 % (2/7) of the IFIs were caused
by C. albicans in the control group, there was only one
patient with an IFI (8.3 %) caused by C. albicans in the
Fig. 1 Flowchart of included extremely low birth weight infants
during the study period
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fluconazole group (P = 0.52). Two infants infected with
fluconazole-resistant C. glabrata eventually died as the
direct result of the IFI, no matter which group they were
involved.
Efficacy outcomes
The primary efficacy outcome, IFI incidence was not sig-
nificantly different between the two groups (5.0 % vs.
4.4 %, P = 0.80). This finding was consistent when ap-
plied to infants with birth weight <750 g (9.1 % vs.
8.8 %, P = 0.95). This result did not change when IFIs
were evaluated as the number of events per 1,000
patient-days (Table 3).
Mortality and the rates of death from an IFI did not
differ between the two groups (11.7 % vs. 16.4 %, P =
0.18 and 3.2 % vs. 11.5 %, P = 0.32, respectively). The
fungal colonization rate was significantly lower in the
fluconazole group (33.9 % vs. 59.1 %, P <0.001). How-
ever, the conversion ratio of fungal colonization to inva-
sive infection did not differ between the two groups
(7.9 % vs. 4.6 %, P = 0.52). The hospitalization duration
was similar between the two groups (mean ± SD, 88 ± 52
vs. 90 ± 51 days, P = 0.74).
Post hoc analysis to evaluate the impact of fluconazole
use for IFI prophylaxis demonstrated that it did not de-
crease IFI risk (adjusted OR = 1.92, 95 % CI = 0.30-12.23,
P = 0.49). Multivariate logistic regression analysis re-
vealed that the risk factors for IFI were low gestational
age (adjusted OR = 0.87, 95 % CI = 0.80-0.95, P = 0.002),
a longer duration to reach full enteral feeding (adjusted
OR = 1.06, 95 % CI = 1.02-1.09, P = 0.001), and necrotiz-
ing enterocolitis requiring surgical intervention (adjusted
OR = 7.34, 95 % CI = 2.00-26.95, P = 0.003) (Table 4).
Safety outcomes
The proportion of IFIs caused by fluconazole-resistant
strains was higher in the fluconazole group compared
with the control group, but this difference did not reach
statistical significance (50.0 % vs. 14.3 %, P = 0.17). IFIs
involving natively fluconazole-resistant strains (C. krusei
and C. glabrata) were not more frequent during flucon-
zole prophylxis. IFIs involving fluconazole-resistant C.
Table 1 Demographic and clinical characteristics
Pre-prophylaxis (n = 159) Fluconazole prophylaxis (n = 264) P value
Baseline characteristics
Gestational age, mean ± SD, week 27+1 ± 2+3 27+0 ± 2+1 0.99
Birth weight, mean ± SD, g 761 ± 153 775 ± 154 0.32
Multiples 72 (45) 119 (45) 0.97
Vaginal delivery 42 (26) 80 (30) 0.39
Small for gestational age (<10 percentile) 69 (43) 112 (42) 0.85
Antenatal steroid use 108 (72) 229 (87) <0.001
Antenatal antibiotic use 65 (41) 126 (48) 0.19
Maternal chorioamnionitis 46 (31) 97 (37) 0.16
Maternal preeclampsia 38 (24) 65 (25) 0.91
Maternal diabetes 7 (5) 7 (3) 0.32
Clinical courses
Bronchopulmonary dysplasia 89 (60) 152 (63) 0.56
Necrotizing enterocolitis (surgical) 16 (10) 23 (9) 0.63
Intraventricular hemorrhage (≥ grade 2) 28 (18) 58 (22) 0.32
Retinopathy of prematurity 70 (49) 134 (56) 0.23
Invasive bacterial infection 47 (30) 82 (32) 0.67
Full feeding reach (≥100 mL/kg/d), mean ± SD, day 31 ± 17 26 ± 16 0.001
H2 blocker use 109 (69) 104 (39) <0.001
Oxygen therapy > 48 hours 150 (94) 230 (87) 0.02
Intubation > 48 hours 127 (80) 198 (75) 0.28
Umbilical lines at postnatal 3rd day 22 (14) 35 (13) 0.85
Antibiotic duration, mean ± SD, day 28 ± 26 19 ± 20 <0.001
3rd generation cephalosporin use 42 (26) 12 (5) <0.001
Vancomycin use 95 (60) 128 (49) 0.03
Values are reported as n (%) unless otherwise indicated
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parapsilosis were much increased during the fluconazole
prophylaxis period, but also did not reach statistical sig-
nificance (41.7 % vs. 0 %, P = 0.11). Colonization by
fluconazole-resistant fungi and natively fluconazole-
resistant strains was similar between the two groups.
There were no between-group differences in the number
of infants with liver dysfunction, renal dysfunction, cho-
lestasis, rickets of prematurity, or rash. Late morbidities
evaluated at 18 to 22 months corrected age, including
cerebral palsy, blindness, deafness and catch up growth
Table 2 Details of invasive fungal infection events
Patient Organism Fluconazole-resistance Onset day Site of Infection Mortality Cause of Death
During the pre-prophylaxis period
1 Candida albicans Sensitive 8, 39 Blood Died Invasive fungal infection
2 Candida parapsilosis Sensitive 18 Blood Alive
3 Candida parapsilosis Sensitive 7 Blood Alive
4 Candida parapsilosis Sensitive 13 Blood Alive
5 Candida glabrata Resistant 13 Blood Died Invasive fungal infection
6 Candida glabrata Sensitive 11 Blood Alive
7 Candida albicans Sensitive 8 Blood, urine Died Invasive fungal infection
During the fluconazole prophylaxis period
8 Candida parapsilosis Sensitive 32 Blood, urine Alive
9 Candida glabrata Resistant 19 Blood Died Invasive fungal infection
10 Candida parapsilosis Resistant 24 Blood, ascites Died Cardiac failure, NECa
11 Candida parapsilosis Resistant 28 Blood Died Unknown
12 Candida glabrata Sensitive 8 Blood Alive
13 Candida parapsilosis Sensitive 21 Blood Alive
14 Candida parapsilosis Sensitive 6 Blood Alive
15 Candida albicans Sensitive 21 Blood, urine Alive
16 Candida parapsilosis Resistant 43, 71 Blood Alive
17 Candida parapsilosis Resistant 11 Blood Alive
18 Candida parapsilosis Resistant 17 Blood Alive
19 Candida parapsilosis Sensitive 12 Blood Alive
a Necrotizing enterocolitis
Table 3 Efficacy outcomes of fluconazole prophylaxis
Pre-prophylaxis Fluconazole prophylaxis P value
Primary outcomes
Invasive fungal infection 7/159 (4.4) 12/242 (5.0) 0.80
Invasive fungal infection in birth weight <750 g 6/68 (8.8) 9/99 (9.1) 0.95
Invasive fungal infection, event per 1,000 patient days 0.56 0.56 0.99
Secondary outcomes
Death 26/159 (16.4) 31/264 (11.7) 0.18
Death from invasive fungal infection 3/26 (11.5) 1/31 (3.2) 0.32
Invasive fungal infection related death 2/7 (28.6) 1/12 (8.3) 0.52
Baseline fungal colonization 4/149 (2.7) 3/224 (1.3) 0.71
Fungal colonization 88/149 (59.1) 76/224 (33.9) <0.001
Single:Multiple(≥2 sites) 21:67 17:59 0.44
Axilla:Ear:Nasopharynx:Throat/trachea:Anus:Urine 46:25:2:8:29:14 33:19:4:10:19:15 -
Fungal colonization to invasive infection 4/88 (4.6) 6/76 (7.9) 0.52
Length of hospitalization, mean ± SD, day 90 ± 51 88 ± 52 0.74
Values are reported as n/total (%) unless otherwise indicated
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failure, were not significantly different between the two
groups (Table 5).
Discussion
In this retrospective cohort analysis conducted over a 10-
year period, although it lowered the fungal colonization
rate significantly, fluconazole prophylaxis did not reduce
the incidence of IFIs in ELBW infants. In addition, al-
though the increase did not reach statistical significance,
fluconazole prophylaxis tended to increase the incidence
of invasive infections involving fluconazole-resistant C.
parapsilosis (41.7 % vs. 0 %, P = 0.11). This discrepant re-
sult might be related to other infection control areas or
presence of other source of fungal infection during flucon-
azole prophylaxis period. However, there were no changes
in infection control practices during whole study periods
and the incidence of invasive bacterial infection was simi-
lar between two periods. In addition, the fact that
fluconazole-received infants had less exposure to well-
known risk factors for IFIs (e.g., the prolonged use of
Table 4 Analysis on the risk for invasive fungal infection
Unadjusted OR (95 % CI) Adjusted ORa (95 % CI) P valueb
Fluconazole prophylaxis 1.13 (0.43–2.94) 1.92 (0.30–12.23) 0.49
Gestational age 0.90 (0.86–0.95) 0.87 (0.80–0.95) 0.002
Birth weight 1.0 (0.99–1.0) 1.0 (0.99–1.01) 0.76
Antepartum antibiotic use 7.13 (2.04–24.9) 10.85 (0.94–125.50) 0.06
Umbilical line at postnatal 3rd day 4.44 (1.65–11.95) 0.68 (0.10–4.86) 0.70
H2 blocker use 3.83 (1.25–11.75) 0.76 (0.09–6.09) 0.79
Full feeding reach (≥100 mL/kg/d) 1.05 (1.03–1.08) 1.06 (1.02–1.09) 0.001
Necrotizing enterocolitis (surgical) 8.34 (3.12–22.31) 7.34 (2.00–26.95) 0.003
Invasive bacterial infection 4.89 (1.81–13.18) 1.55 (0.29–8.37) 0.61
Antibiotic duration 1.03 (1.02–1.05) 1.02 (1.00–1.05) 0.09
Vancomycin use 16.55 (2.19–125.23) 3.63 (0.30–43.33) 0.31
a Multivariate logistic regression analysis was done with stepwise method
b for adjusted OR
Table 5 Safety outcomes of fluconazole prophylaxis
Pre-prophylaxis Fluconazole prophylaxis P value
Invasive fungal infection by fluconazole-resistant strains 1/7 (14.3) 6/12 (50.0) 0.17
Invasive fungal infection by natively fluconazole-resistant strainsa 2/7 (28.6) 2/12 (16.7) 0.60
Invasive fungal infection by fluconazole-resistant C. parapsilosis 0/7 (0) 5/12 (41.7) 0.11
Fungal colonization by fluconazole-resistant strains 4/25 (16.0) 9/55 (16.4) >0.99
Fungal colonization by natively fluconazole-resistant strainsa 10/88 (11.4) 9/76 (11.8) 0.92
Acute adverse events
Liver dysfunction (AST or ALT > 250 U/L)b 8/156 (5.1) 11/262 (4.2) 0.66
Renal dysfunction (creatinine > 1.5 mg/dL)b 34/155 (21.9) 46/262 (17.6) 0.27
Cholestasis (direct bilirubin > 2 mg/dL)b 10/74 (13.5) 24/238 (10.1) 0.41
Skin rashb 10/150 (6.7) 16/262 (6.1) 0.84
Rickets of prematurityc 24/100 (24.0) 70/177 (39.4) 0.63
Late morbidities at 18 to 22 months corrected age
Cerebral palsy 8/126 (6.4) 28/222 (12.6) 0.11
Blindness, at least one eye 0/131 (0) 0/230 (0) -
Deafness, at least one ear 0/132 (0) 2/227 (0.9) 0.54
Failure to catch up growth (<10 percentile) 52/108 (48.2) 87/192 (45.3) 0.64
Values are reported as n/total (%) unless otherwise indicated
a C. krusei and C. glabrata
b Episodes occurred during 6 weeks after birth were counted
c Documented by the wrist X-ray at 4 weeks of age
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broad spectrum antibiotic, H2 blocker, and delayed enteral
feeding completion) raise the question regarding the effi-
cacy of fluconazole prophylaxis.
In agreement with other investigations, our study
showed that advanced necrotizing enterocolitis and a
longer duration to reach to full enteral feeding increased
the odds of developing an IFI. However, fluconazole
prophylaxis did not decrease the risk of IFI development
(adjusted OR = 1.92, 95 % CI = 0.3-12.23) in ELBW in-
fants. Notably, the IFI incidences markedly varied be-
tween the NICUs (ranging from <2 to 30 %) [3–10, 20,
21], and the potential benefits of fluconazole prophylaxis
may be less in centers with a low incidence of IFIs. The
pre-prophylaxis period exhibited a 4.4 % (unit 1, 4.7 %;
unit 2, 3.3 %) incidence of proven invasive candidiasis in
this study. Fluconazole has been shown to be very effect-
ive in preventing candidiasis in previous studies with
high incidences of IFIs (13 % [6] and 20 % [5] in the
fluconazole-untreated groups). However, the fluconazole
use for antifungal prophylaxis in NICUs with a low inci-
dence of IFIs is controversial. The latest guidelines of
the European Society of Clinical Microbiology and Infec-
tious Diseases (2012) recommend fluconazole prophy-
laxis of 3-6 mg/kg/dose twice weekly intravenously or
orally for neonates <1,000 g only for NICUs with rela-
tively high frequency of IFIs [22]. For NICUs with a
lower incidence (<2 %) of IFIs, this guideline recom-
mends that the decision should be made on a case-by-
case basis and embedded in a risk stratification strategy
(e.g., additional risk factors for IFIs, such as central ven-
ous catheterization and the receipt of third-generation
cephalosporins or carbapenems) [22].
There is concern regarding the emergence of a fungal
ecological shift toward Candida spp. (C. glabrata or C.
krusei) with intrinsic resistance to fluconazole [13, 23].
In this study, the routine administration of fluconazole
prophylaxis for 4 weeks to all ELBW infants for a
period of 5 years did not lead to selection for the
colonization with C. glabrata or C. krusei, which are
natively resistant to fluconazole (Table 5). However,
from the non-prophylaxis era to the fluconazole
prophylaxis period, we detected a shift in Candida spe-
cies causing invasive infection from a majority of C.
albicans to entirely non-albicans species. There was a
decrease in the rate of invasive infection by C. albicans
(28.6 % to 8.3 %), with a corresponding increase in C.
parapsilosis infections (42.9 % to 75.0 %) and its flucon-
azole resistance (0 % to 55.6 %) after routine flucona-
zole exposure over a 5-year period (Table 2). This
change in the distribution of Candida species might be
concomitant with a reduction in C. albicans-attribut-
able infections, given that this species is exquisitely sus-
ceptible to fluconazole. However, one animal study has
reported an increase in the occurrence of fluconazole-
resistant C. parapsilosis infections after a 4-year period
of antifungal prophylaxis in a premature animal NICU [24].
Similarly, Sarvikivi et al. reported that the prolonged
(>10 years) use of fluconazole for prophylaxis in a NICU re-
sulted in the emergence of resistant C. parapsilosis [25]. In
addition, a negative correlation has been found between flu-
conazole consumption and the rate of C. parapsilosis
bloodstream infections [25]. Moreover, in an Indian NICU
at which fluconazole prophylaxis had been used routinely
for the preceding 6 years, the most common fungal isolates
causing invasive infections were non-albicans Candida spe-
cies with relatively reduced azole susceptibility [26]. This
pattern of resistance was also observed in critically ill adults
who had received antifungal prophylaxis [27].
However, many studies that evaluate the effect of flu-
conazole prophylaxis in preterm infants have not ob-
served any statistically significant difference on fungal
resistance patterns [13, 19, 28–30]. Although it is
guessed several known mechanisms, which has been
described as manners of acquired resistance for the
azoles in Candida spp., might act in concert leading to
stepwise increases in minimum inhibitory concentra-
tions (MICs) and broadening of the azole resistance
spectrum during long term exposure to fluconazole
[31–33], there is conflict on how it may impact to local
epidemiology trends in Candida spp. with a cross-
patient delivery of antifungal resistance in NICUs. Add-
itionally, as C. parapsilosis is associated with parenteral
nutirion preparation and possible horizontal transmis-
sion via NICU staffs, infection preventive measures of
each unit might be more contributable to the pattern
changes of local epidemiology in Candida spp. Ten-
year data from the National Nosocomial Infections Sur-
veillance System of the United States has demonstrated
decreases in the incidences of candidemia and invasive
infections due to both C. albicans and C. parapsilosis
in ELBW infants, and no changes in the incidences of
infections involving other Candida spp [34]. There is a
need for prospective studies to measure the long-term
effect of fluconazole prophylaxis on antifungal resist-
ance patterns. Additionally, on-going local and national
efforts to detect the emergence of resistant organisms
are needed [7].
Several limitations of this study should be consid-
ered. First, this was an uncontrolled observational
study conducted in two NICUs. Confounding factors
cannot be excluded, but the roles of any possible un-
identified confounding variables are thought to be
minimal and infection control policies were consist-
ently applied for all infants during the study period.
Second, our study design did not include routine MIC
testing or the subtyping of DNA from obtained iso-
lates. Third, potentially starting fluconazole prophy-
laxis earlier, on the day of life 1 or 2 would work
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better than 3 day in this study. There is a report that
demonstrates the superior efficacy when starting anti-
fungal prophylaxis within 48 hours after birth, prior to
colonization [35]. At last, it is difficult to evaluate the
actual culturing activity in NICUs over such a long
time period. Invasive candidiasis is detected at a low
sensitivity in blood cultures [36]. The small blood vol-
umes used in the culture studies may have exacerbated
this low diagnostic sensitivity and caused the selective
under-diagnosis of IFIs in premature infants. For as-
certaining the hidden effects of IFIs, we evaluated all-
cause mortality, which is not affected by this bias, and
found no statistically significant effect of fluconazole
prophylaxis on mortality rates.
Conclusions
Our results discourage the routine use of fluconazole
prophylaxis for ELBW infants in NICUs with a low IFI
incidence. However this study is one of many studies
that evaluate the effect of fluconazole prophylaxis in pre-
term infants, in which mostly have not demonstrated re-
sistance. Even if preventing invasive Candida infections
that are associated with high mortality and neurodevelo-
pemental impairment needs to remain a focus in ever
NICU, its long-term effects should be carefully evalu-
ated. Having knowledge of local epidemiologic trends in
Candida spp. and monitoring of fungal isolates for drug
resistance would be essential and further prospective
studies are needed to examine fluconazole resistance
patterns in premature infants.
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